JacalynMRosenblattMD

Hematology • Boston, MA

Assistant Professor, Medicine-Beth Israel Deaconess Medical Center, Harvard Medical School

Join to view full profile

Dr. Rosenblatt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rosenblatt's full profile

Already have an account?

Office
330 Brookline Avenue, Ks-121
Beth Israel Deaconess Hospital
Boston, MA 02215
Phone+1 617-667-9920

Education & Training

McGill University Faculty of MedicineClass of 1997

Certifications & Licensure

MA State Medical License 2003 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission Start of enrollment: 2010 May 01
Active, not recruiting
Phase 2
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) Start of enrollment: 2011 Sep 01
Terminated
Phase 1
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro Start of enrollment: 2010 Oct 01
Completed
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2012 Feb 01
Unknown status
Phase 1, Phase 2
Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD) Start of enrollment: 2014 Mar 27
Completed
Phase 1
Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT Start of enrollment: 2014 Apr 01
Terminated
Phase 1
GO-203-2C + Bortezomib For Relapsed Or Refractory MM
Withdrawn
Phase 1
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission Start of enrollment: 2017 Jun 01
Recruiting
Phase 2
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients Start of enrollment: 2018 Oct 11
Recruiting
Phase 1
KRDI in Transplant-Eligible MM Start of enrollment: 2020 Jul 10
Active, not recruiting
Phase 2
Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2020 Nov 30
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

996 citations
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje, Jesus G. Berdeja, Yi Lin, David S. Siegel, Sundar Jagannath
The New England Journal of Medicine. 2019-05-01
123 citations
Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions.
Jacalyn Rosenblatt, Richard Stone, Lynne Uhl, Donna Neuberg, Robin Joyce
Science Translational Medicine. 2016-12-07
46 citations
Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine.
Myrna Nahas, Dina Stroopinsky, Jacalyn Rosenblatt, Leandra Cole, Athalia Rachel Pyzer
British Journal of Haematology. 2019-03-03

Abstracts/Posters

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
Jacalyn Rosenblatt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine
Jacalyn Rosenblatt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy
Jacalyn Rosenblatt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma
Jacalyn Rosenblatt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells
Jacalyn Rosenblatt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematologi...
Jacalyn Rosenblatt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Immune Checkpoints in Myeloid Malignancies
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all